Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

Blood

Volumn 110, Issue 2, 2007, Pages 536-543

  Zauli, Giorgio ^a   Corallini, Federica ^a   Bossi, Fleur ^a   Fischetti, Fabio ^a   Durigutto, Paolo ^a   Celeghini, Claudio ^a   Tedesco, Francesco ^a   Secchiero, Paola ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HEPARIN LYASE; N ACETYLGALACTOSAMINE 4 SULFATASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMINO TERMINAL SEQUENCE; ARTICLE; CAPILLARY; CELL STRAIN HL 60; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; LIGAND BINDING; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN;

EID: 34547129112     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-068395     Document Type: Article

References (42)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
2. Boyle WJ, Scott SW, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
3. Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-κB ligand. J Biol Chem. 2005;280:41155-41164.
4. Emery JG, McDonnell P, Brigham Burke M, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367.
5. Zauli G, Secchiero P. The role of the TRAIL/TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006;17:245-257.
6. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003;14:337-348.
7. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62:1619-1623.
8. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86:269-279.
9. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63:912-916.
10. Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R. Disabling of receptor activator of nuclear factor-kB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem. 2004;279:8269-8277.
11. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194.
12. Schoppet M, Sattler AM, Juergen R, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-1028.
13. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-1976.
14. Ueland T, Yndestad A, Øie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468.
15. Crisafulli A, Micari A, Altavilla D, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci. 2005;109:389-395.
16. Moran CS, McCann M, Karan M, Normal P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005;111:3119-3125.
17. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006;169:2236-2244.
18. Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518.
19. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2002;8:2306-2310.
20. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate. 2004;59:304-310.
21. Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118:1901-1908.
22. Zauli Pandolfi A, Gonelli A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res. 2003;92:732-740.
23. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood. 2005;105:3413-3419.
24. Dobrina A, Pausa M, Fischetti F, et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood. 2002;99:185-192.
25. Shriver Z, Sundaram M, Venkataram G, et al. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci U S A. 2000;97:10365-10370.
26. Fagerholm SC, Varis M, Stefanidakis M, Hilden TJ, Gahmberg CG. α-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation in vivo. Blood. 2006;108:3379-3386.
27. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273:5117-5123.
28. Théoleyre S, Kwan Tat S, Vusio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kB ligand (RANKL) and RANK. Biochem Biophys Res Commun. 2006;347:460-467.
29. Mosheimer BA, Kaneider NC, Feistritzer C, et al. Syndecan-1 is involved in osteoprotegerininduced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90:2964-2971.
30. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002;521:180-184.
31. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005;48:561-568.
32. Fu M, Zhang J, Lin Y, Zhu X, Willson TM, Chen YE. Activation of peroxisome proliferator-activated receptor γ inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun. 2002;294:597-601.
33. Malyankar U, Scatena M, Suchland K, Yun T, Clark E, Giachelli C. Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-20962.
34. -/-. Arterioscler Thromb Vasc Biol. 2006;26:2117-2124.
35. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
36. Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res. 2005;96:792-799.
37. Woods A, Couchman JR. Syndecans: synergistic activators of cell adhesion. Trends Cell Biol. 1998;8:189-192.
38. Secchiero P, Sun D, De Vico A, et al. Evidence for a role of the extracellular domain of human herpesvirus 7 glycoprotein B in the viral binding to cell surface heparan sulfate proteoglycans. J Virol. 1997;71:4571-4580.
39. Landmesser U, Hornig B, Drexler H. Endothelial function. A critical determinant in atherosclerosis? Circulation. 2004;109:27-33.
40. Soufi M, Schoppet M, Sattler AM, et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab. 2004;89:3764-3768.
41. Secchiero P, Candido R, Corallini F, et al. Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 2006;114:1522-1530.
42. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276:20659-20672.